Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1981-01-09
1983-06-21
Hazel, Blondel
Drug, bio-affecting and body treating compositions
Lymphokine
424177, 424180, 2601125R, 536270, A61K 4502, C07C10352
Patent
active
043893953
ABSTRACT:
A nuclease resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid, poly-l-lysine and carboxymethylcellulose, wherein the nucleotide homopolymers have sedimentation coefficients of 4S and each homopolymer has a molecular weight of about 25,000 or less. When administered in a pharmacologically acceptable aqueous carrier, such as a saline solution, the complex is effective in inducing the synthesis of antiviral levels of interferon in the host, while modulating the toxicity reactions normally associated with the administration of greater molecular weight complexes of polyriboinosinic-polyribocytidylic acid, particularly hypotension.
REFERENCES:
patent: 3679654 (1972-07-01), Maes
patent: 3952097 (1976-04-01), Levy
patent: 4018916 (1977-04-01), Hodge
patent: 4024222 (1977-05-01), Ts'o et al.
patent: 4124702 (1978-11-01), Lanpson et al.
patent: 4130641 (1978-12-01), Ts'o et al.
patent: 4224241 (1977-05-01), Levy
Gatmaitan, B. G., et al., Antimicrob. Ag. Chemother., vol. 17, pp. 49-54, 1980, and vol. 18, pp. 409-415, 1980.
Champney, K., et al., Injection and Immunity, vol. 25, pp. 831-837, 1979.
Lerner A. Martin
Levy Hilton B.
LandOfFree
Low molecular weight complex of polyriboinosinic-polyribocytidyl does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Low molecular weight complex of polyriboinosinic-polyribocytidyl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low molecular weight complex of polyriboinosinic-polyribocytidyl will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2110603